Darunavir Now Available in 600-mg Tablets
HIV/AIDS Clinical Care Drug Watch
Free Article
The FDA has approved a new strength of darunavir that will reduce pill burden: The drug is now available in 600-mg tablets, as well as . . .
Revised Package Insert for Atazanavir
HIV/AIDS Clinical Care Drug Watch
Free Article
The insert includes new information on administering the drug with acid-reducing therapies and on appropriate dosing in patients with renal failure.
FDA Approval: Etravirine
HIV/AIDS Clinical Care Drug Watch
Free Article
Etravirine is highly effective against most viruses with resistance to other NNRTIs. Clinicians will need to be especially aware of the determinants of cross-resistance and of some significant drug–drug interactions.
Lower Dose of Ritonavir Approved for Use with Fosamprenavir
HIV/AIDS Clinical Care Drug Watch
Free Article
The FDA recently approved a new dosing strategy for use in treatment-naive patients: 1400 mg of fosamprenavir with 100 mg of ritonavir, both taken once daily.
Raltegravir, a New HIV Integrase Inhibitor
HIV/AIDS Clinical Care Drug Watch
Free Article
Because raltegravir inhibits a novel viral target, even HIV that is resistant to other antiretroviral-medication classes is sensitive to this drug.
Caution Regarding Nelfinavir Use in Children and Pregnant Women
HIV/AIDS Clinical Care Drug Watch
Free Article
The discovery of a potential carcinogen in nelfinavir has prompted new recommendations regarding use of this drug.
By ACC Editors
September 24, 2007
FDA Approval: Maraviroc
HIV/AIDS Clinical Care Drug Watch
Free Article
The CCR5 antagonist maraviroc is an important new option for treatment-experienced patients — as long as they harbor CCR5-tropic virus.
New Safety Information for Erythropoiesis-Stimulating Agents
HIV/AIDS Clinical Care Drug Watch
Free Article
ESAs should be given at the lowest possible effective dose, and hemoglobin levels should be monitored regularly at treatment initiation and after any dose adjustments.
By ACC Editors
March 19, 2007
Entecavir in HIV/HBV Coinfection: Possible Resistance When Used Alone
HIV/AIDS Clinical Care Drug Watch
Free Article
Entecavir, a drug previously thought to have exclusive HBV activity, has now been shown to have anti-HIV activity and hence potentially to select for HIV resistance if not given with concomitant antiretroviral therapy.
By Paul E. Sax, MD
March 5, 2007
New Package Inserts for Efavirenz and T-20
HIV/AIDS Clinical Care Drug Watch
Free Article
New information highlights the potential for drug–drug interactions with efavirenz and for injection-site reactions with T-20.
By ACC Editors
February 5, 2007
